LDLR and metabolic dysfunction-associated steatohepatitis: Although PCSK9 inhibition reduces plasma LDL-c and maintains LDLR expression in hepatocytes, it also increases liver exposure to cholesterol, potentially heightening the risk of MASH and HCC.